

1 Identification of Mycoplasma in the Cerebro-Spinal Fluid (CSF) 2 Sample from a Patient with Multiple Sclerosis (MS)

3 ¹Hossein Ali Ebrahimi² Babak Kheirkhah³Parisa Seyfadini

4 ¹Professor Neurology Research Center, Kerman University of Medical Sciences,
5 Kerman, Iran

6 ²Assisted professor, Department of Medical Sciences, Islamic Azad University Sirjan
7 Branch, Sirjan, Iran

8 ³MSc of Microbiology, Department of Medical Sciences, Islamic Azad University
9 Sirjan Branch, Sirjan, Iran

10 Corresponding Author Email: hebrahimi@kmu.ac.ir

11 Abstract

12 Background and aim: Multiple sclerosis (MS) is a complex neurological condition,
13 characterized by demyelination and axonal loss. MS is the most common human
14 demyelinating disease. The etiology of MS is unknown, but a lot of factors are
15 considered. There are many studies on viral, bacterial and other factors one of which
16 is Mycoplasma infections. In this study, we evaluated the mycoplasma pneumonia in
17 cerebro-spinal fluid (CSF) of MS patients in the attack course. Methods: In this
18 descriptive study, with the purposive sampling of CSF from 60 patients diagnosed with
19 MS to diagnosis by the physician) by PCR identification method. Results: PCR
20 identification of Mycoplasma species in a total of 42 enriched samples successful in 1
21 strain and showed specific amplicon at 163 bp. Conclusion: Mycoplasma pneumonia
22 may be one of the causes or trigger

23 **Keywords:** mycoplasma pneumonia, Multiple sclerosis, MS, CSF, PCR

25 Introduction

26 age adults. MS is estimated to affect
45 400,000 persons in the United States and 2
46 million people worldwide. Women are
47 affected twice as frequently as men,
48 between the ages of 20 and 40, and whites
49 are especially those of northern European
50 extraction.

51 Generally accepted hypothesis is that MS
52 is secondary to an autoimmune response to
53 self-antigens in a genetically susceptible
54 host. It should be pointed out that the
55 inflammation found in the CNS of patients
56 with MS is thought to represent an
57 autoimmune response (7). There were
58 thought to possibilities regarding the
59 initiating event in MS. The first is that the
60 CNS white matter is structurally normal,

27 Multiple sclerosis (MS) is an inflammatory
28 disease limited to the central nervous
29 system (CNS) white matter. MS is a
30 chronic demyelinating disease of the
31 central nervous system. Studies have
32 shown that MS is a result of immune
33 reaction that happens in a susceptible
34 genetic condition (1-2). The inflammation
35 varies among different patients, and
36 consists of variable degrees of T
37 lymphocytes, macrophages, B
38 lymphocytes, and antibodies at the leading
39 edge of the white matter destruction (3-4).
40 MS is the most common inflammatory-
41 demyelinating disease of the CNS and the
42 most frequent cause of non-traumatic
43 neurologic disability in young and middle-

39 arthritides (8-12-18). Patients with chronic
40 fatigue syndrome, as a major sign, often
41 have different clinical diagnoses, but
42 display overlapping signs/symptoms
43 similar to many of those found in CSF,
44 FMS, and MS
45 There is some preliminary evidence that
46 mycoplasmal infections are associated
47 with various autoimmune diseases. In
48 some mycoplasma-positive GWI cases
49 signs and symptoms of MS, Amyotrophic
50 Lateral Sclerosis (ALS), Lupus, Graves's
51 disease, and other complex autoimmune
52 disease have been seen. Such
53 usually rare autoimmune responses are
54 consistent with certain chronic infections,
55 such as mycoplasma infections, that
56 penetrate into nerve cells synovial cells,
57 and other cell types. The autoimmune
58 signs and symptoms could be the result of
59 intercellular pathogens, such as
60 mycoplasmas, escaping
61 from cellular compartments and
62 incorporating into their own structures
63 pieces of host cell membranes that contain
64 important host antigens that can trigger
65 autoimmune responses. Alternatively,
66 mycoplasma surface components,
67 sometimes called super-antigens, may
68 directly stimulate autoimmune responses.
69 Perhaps the most important event, the
70 molecular mimicry of host antigens by
71 mycoplasma surface components, may
72 explain, in part, their ability to stimulate
73 autoimmune responses (19). We used PCR
74 (polymerase chain reaction) to determine
75 the presence of mycoplasma genus in CSF
76 of patients in Kerman province, Iran.

77

78 **Material and methods**

87 system can support, supplement, or even
88 replace some clinical criteria (22-23), as
89 recently emphasized by the so-called
90 McDonald Criteria of the International
91 Panel on Diagnosis of MS (23-24). The
92 McDonald Criteria have resulted in earlier
93 diagnosis of MS with a high degree of
94 both specificity and sensitivity (25-26),

1 and that an autoimmune response is
2 initiated by auto-reactive T cells. The
3 second possibility is that the inflammation
4 is a result of some alteration of the CNS
5 white matter, which could be the result of
6 a microbial CNS infection.

7 The trigger of showing immunity
8 responses is totally unknown, but some
9 factors are considered as contributing, such
10 as personal factors (age, sex hormones)
11 and environmental factors, including
12 vitamin D deficiency, smoking, previous
13 infection by Epstein-Barr Virus (EBV),
14 contact to metals living in high prevalence
15 ecological regions and cold weather (8-9-
16 10). The prevalence of MS in Kerman is
17 nearly 60 cases Chemokine and
18 interleukins play an important role in the
19 autoimmune diseases (12-13-14-15).
20 Mycoplasma may have a role in triggering
21 Mycoplasmas (class Mollicutes) lack a
22 rigid cell wall and are bound by a single
23 membrane, the plasma membrane. Wall-
24 less bacteria were first described years
25 ago, and now 190 species, widely
26 distributed among humans, animals,
27 insects and plants, are known (17).
28 Mycoplasmas can cause acute disease at
29 multiple sites with wide-ranging
30 complications and have been implicated as
31 cofactors in disease. Recently,
32 Mycoplasmas have been linked as a
33 cofactor to AIDS pathogenesis and to
34 malignant transformation, chromosomal
35 aberrations, the Gulf War illness (GWI),
36 and other unexplained and complex
37 illnesses, including chronic fatigue
38 syndrome, Crohn's disease, and various

79 MS Diagnosis: Diagnostic criteria for MS
80 include clinical and paraclinical laboratory
81 assessments (20-21), emphasizing the need
82 to dissemination of lesions in space (DIS)
83 and time (DIT) and to exclude alternative
84 diagnoses. Although the diagnosis can be
85 made on clinical grounds alone, magnetic
86 resonance imaging of the central nervous

50 min. The tube and an equal volume of
51 mixed phenol/cholorophorm (1:1) was
52 added. After centrifuging at 13 000rpm for
53 20 min, the aqueous
54 transferred to another tube to which an
55 equal volume of pure cholorophorm was
56 added, and then centrifuged at 13 000 rpm
57 for 5 min. was transferred to a new tube,
58 mixed with 1/10 volume of acetate sodium
59 (3 M) and was precipitated in a -20øC
60 refrigerator with a 2-fold cool and pure
61 ethanol (20 min). Next, the tube was
62 centrifuged at 13 000 rpm for 15 min. 200
63 æL of 70% ethanol was at 13 000 rpm for
64 5 min, and finally, the DNA was dried and
65 re-suspended in DDW at 4øC to be used.

66 PCR: For mycoplasma genus,
67 amplification of the 16S rRNA gene was
68 performed with a pair of primers
69 complementary to the regions close to the
70 5' the 3' termini of the gene. DNA
71 amplification was carried out in a total
72 volume of 35.25æL, containing 17.5æL of
73 DNA, 0.1æL of each primer, 0.5æL dNTP
74 mix (10mM) {Roche}, 4æL Mgcl₂ (25mM)
75 {Roche}, 2.5æL PCR buffer (10x)
76 {Roche}, and 0.25æL Tag DNA
77 polymerase (5unit/æL) {Roche}. The
78 reaction mixture was thermo-cycled. The
79 thermal-cycling conditions for
80 Mycoplasma strain were as follows: 95øC
81 for 6 min, followed by 35 cycles of 94øC
82 min, 55øC for 1 min, and 70øC, for one
83 minute. The PCR products were stored at
84 4øC. Negative and positive controls were
85 PPLO broth media and standard strain of
86 M. Pneumonia were included in all tests.
87 Each microliter aliquot of every PCR
88 product was mixed with 2æL of the loading
89 buffer (6x The PCR products and a 100bp
90 DNA ladder were, then, separated by
91 electrophoresis on 1% agarose gel and
92 stained with 0.5æL/ml ethidium bromide
93 volts for 1hr), following a UV
94 transluminator From the work on
95 mycoplasma genus amplification, two
96 designed primers (forward and reverse),
97 were used; a 163bp region of 16S rRNA
98 gene was amplified

1 allowing for better counseling of patients
2 and treatment.

3 Since the revision of the McDonald
4 Criteria in 2005, new data and consensus
5 have pointed to the need for their
6 simplification to improve comprehension
7 and utility and for evaluating their
8 appropriateness in populations that differ
9 from the largely Western Caucasian adult
10 populations from which the Criteria were
11 derived. In May 2010, in Dublin, Ireland,
12 the International Panel on Diagnosis of
13 MS (the Panel) met for a third time
14 examine requirements for demonstrating
15 DIS and DIT and to focus on the
16 application of the McDonald Criteria in
17 pediatric, Asian, and Latin American
18 populations.

19 Mycoplasma isolation: In this descriptive
20 study, the purposive CSF sampling from
21 42 patients diagnosed with MS (according
22 to diagnosis by physician) was conducted
23 in the first 6 months of 2013. Following
24 the clinical examination, samples were
25 collected from epidural space. were
26 immediately placed in test tubes with
27 transport Mycoplasma culture medium and
28 were kept at 4øC until they have been
29 transported to the
30 respective department of Pasargad
31 Microbiology Research Group's
32 Microbiology Laboratory within 24 h.
33 Transport media contain thallos acetate
34 (250mg liter), that reduce bacterial
35 contamination of the clinical sample (28).
36 The collected samples in transport culture
37 medium were, then, incubated PPLO broth
38 in order for the primary Mycoplasma to be
39 propagated and enriched in a humid air
40 with 5% CO₂ at 37øC overnight in the
41 DNA extraction: Consequently, DNA was
42 extracted according to the procedures of
43 Kojima (29). 500 æL of the samples were
44 placed in a 1x tube and micro centrifuged
45 at 13 000rpm for 15 min. 100 æL of lyses
46 buffer was added to 100 æL of precipitate,
47 and, the tube was bath for 4 h. Then, 200
48 æL saturated phenol was added and the
49 tube was centrifuged at 13 000 rpm for 20

17 (Annealing) and 72°C for 1 min
18 (Extension), while were finished with a
19 final extension step at 72°C for 10 min.
20 PCR products were stored at 4°C. PCRs
21 were carried out using two programmable,
22 cyclers (Primus and Master gradient).
23 Positive and negative controls were
24 included in all tests. Each µL aliquot of
25 every PCR product was mixed with a 2 µL
26 loading buffer (6X). The PCR products
27 and 100bp DNA ladder were then
28 separated by electrophoresis on 1%
29 agarose gel and stained with ethidium
30 bromide (100 volts for 1h), following a
31 UV


1 For the *M. hominis* species, the primer sets
2 RNAH1 and RNAH2 had already been
3 designed (30) which amplified a 334bp
4 region of lipoprotein gene. Sequences of
5 the primers with their corresponding genes
6 are shown in Table 1. DNA amplification
7 was done in a total volume of 25 µL,
8 DNA, 1 µL of each primer, 0.5 µL dNTP
9 mix (200 mM) (Cinnagen Inc.), 2 µL
10 MgCl₂ (50 mM) (Cinnagen Inc.), 2.5 µL
11 Tag DNA polymerase (5 units/µL)
12 (Cinagen Inc.). The reaction mixture was
13 thermocycled 30 times, beginning with an
14 initial denaturation step minimum 94°C.
15 The temperature and time profile of each
16 cycle was as follows: 94°C for 3min

32 Results

37 obtained from Mycoplasma-positive male
38 and female samples. All of the
39 electrophoresed PCR products were run
40 with positive and negative control

33 PCR identification of Mycoplasma species
34 in a total of 42 enriched samples was
35 successful in 1 strain and showed specific
36 amplicon at shows the bands (163bp)

41



42

43 **Figure 1:** PCR products of Mycoplasma strain on Agarose gel. From left to right: lane +.
44 Mycoplasma positive control. Lane control. Lane 1. Positive male

45 Discussion

57 Six (2.5%) of the CSF samples were
58 positive by PCR amplification. More
59 efforts are necessary to isolate the
60 organism from CSF samples in order
61 ascertain the role of *M. pneumoniae* in
62 causing neurological complications.(31)
63 Another study developed a sensitive two-
64 stage PCR method using nested
65 or semi-nested primers specific for the
66 bacterial 16S ribosomal DNA to test the
67 presence of bacterial DNA in CSF. They

46 In this study, we detected one case of
47 mycoplasma in 42 known MS cases at
48 acute attack. PCR identification of
49 Mycoplasma species in a enriched samples
50 was successful in 1 strain and showed
51 specific amplicon at 163 bp. A similar
52 study attempted to isolate *M. pneumoniae*
53 the organism by PCR from CSF of
54 pediatric patients with Central nervous
55 system manifestations. Of the 244 CSF
56 samples, no *M. pneumoniae* was

33 aseptic meningitis, while, the highest
34 amount was observed in cases with
35 Guillain-Barre syndrome and those with
36 focal neurologic deficit (34). In another
37 study conducted in Iran using ELISA
38 method, IgM and IgG to *M. pneumoniae*
39 were determined in 130 patients with
40 relapsing-remitting MS (85 Remitted
41 phase and 45 Relapsed phase) and 50 sex-
42 controls. The groups were compared with
43 a significant level of $p < 0.05$. The median
44 [interquartile range] titer of IgG in
45 remitted MS
46 RU/ml versus 64 [52.6-71.4] RU/ml in
47 relapsed group and 57.5 [29.2-74.3]
48 RU/ml in the control group ($p = 0.442$).
49 There was difference between the groups
50 based on median titer of IgM too ($P =$
51 0.446). The median [interquartile range]
52 titer of *M. pneumoniae* IgG in RU/ml in
53 remitted patients, versus, 63.85 [52.45-
54 71.25] RU/ml in the relapsed patients, and
55 55.2 [29.17-72.75] RU/ml in controls (p
56 hoc analysis demonstrated significant
57 difference between remitted patients and
58 controls ($p = 0.002$). There was not any
59 significant the men in the groups (p).

60 Conclusion

61 Consequently, we were unable to find
62 evidence for direct CNS infection with *M.*
63 *pneumoniae* in MS

1 designed seven sets of primers to amplify
2 DNA from spirochetes, *Campylobacter*,
3 *Mycoplasma*, *Chlamydia*, *Bartonella*,
4 *Mycobacteria*, and *Streptococcus*, and
5 tested CSF in patients with relapsing-
6 remitting MS, primary progressive MS,
7 transverse myelitis and controls. They did
8 not detect DNA from any of the groups of
9 bacteria in patients or controls (32). In a
10 study, 30 samples of human brain and 57
11 pairs of serum and CSF were examined.
12 No *Mycoplasma*-specific sequence was
13 detected, and the consistent observation of
14 an endogenous gene, human serum
15 albumin (HSA), as a positive control,
16 documented the adequacy of the method.
17 Real-time PCR analysis of serum and CSF
18 was also done, targeting using the
19 *Mycoplasma* 16S rDNA gene, and this,
20 also demonstrated the lack of *Mycoplasma*
21 in these samples. The presence of
22 *Mycoplasma* at extra-neural sites in MS
23 patients is now being explored.(33) A
24 study was carried out in Iran on 55
25 pediatric patients with central nervous
26 system disorders. The CSF anti body level
27 of *M. pneumoniae* significant difference
28 between the cases and the control group
29 (0.08 ± 0.26 versus 0.001 ± 0.001 , $p=0.02$).
30 It showed poor agreement between cases
31 the control group ($Kappa=0.27$). The
32 lowest amount was seen in cases with

References

1. R. Martin, H. F. McFarland, Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis, *Crit. Rev. Clin. Lab. Sci* 1995;32; 121–182.
2. Kampman MT, Brustad M, Vitamin D: a candidate for the environmental effect in multiple sclerosis -observations from Norway, *Neuroepidemiology* 2008;30(3):140-146
3. Ozawa, K, ET al. Patterns of oligodendroglia pathology in multiple sclerosis. *Brain* 1994. 117:1311-1322.
4. Lucchinetti, CF, Bruck, W, Rodriguez, M, Lassmann, H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. *Brain Pathol* 1996. 6:259-274.
5. M, Siva A, Ward J, et al. Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. *Neurology* 1994; 44:28–33
6. Hauser S. Multiple sclerosis and other demyelinating diseases. In: Isselbacher KJ, Martin JB, Fauci AS, et al, eds. *Harrison's principles of internal medicine*. New York: McGraw-Hill; 1994: 2287–95
7. Hafler, DA. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. *J. Clin. Invest.* 1999. 104:527-529. View this article via: JCI.org PubMed CrossRef Google Scholar
8. Karin eliaeson, IVL. Marcus Liljeberg, IVL. Anders Bjork, IVL” et al”, Relationships of geochemistry and multiple sclerosis, Swedish Environmental Research Institute. December 2008:12-31.
9. Spirin NN, Kachura DA, Ershov MB,” et al”, Clinical and epidemiological peculiarities of multiple sclerosis in patients with different level of essential and toxic chemicals in blood serum, *Zh Nevrol Psikhiatrlm S SKorsakova*. 2011:111(2 Pt 2):10-5.
10. Mohammad Ali Shafa, M.D.1, HOssein Ali Ebrahimi, M.D.2*, Narges Khanjani, P.hD.3 A Study of the Seasonal Incidence of Multiple Sclerosis Attacks in Kerman, Iran. *Journal of Kerman University of Medical Sciences*, 2014; 21(5): 376-383
11. Hossein Ali Ebrahimi MD, Behnaz Sedighi MD. Prevalence of multiple sclerosis and environmental factors in Kerman province, Iran. *Neurology Asia* 2013; 18(4): 385 – 389
12. A. Jafarzadeh, S. Bagherzadeh, H. A. Ebrahimi, H. Hajghani, M. R. Bazrafshani, A. Khosravimashizi, M. Nemati, F. Gadari, A. Sabahi, F. Iranmanesh, M. M. Mohammadi, H. Daneshvar. Higher Circulating Levels of Chemokine CCL20 in Patients with Multiple Sclerosis: Evaluation of the Influences of Chemokine Gene Polymorphism, Gender, Treatment and Disease Pattern. *J Mol Neurosci* DOI 10.1007/s12031-013-0214-2
13. A. Jafarzadeh, M. Jamali, R. Mahdavi, H. A. Ebrahimi, H. Hajghani, A. Khosravimashizi, M. Nemati, H. Najafipour, A. Sheikhi, M. M. Mohammadi, H. Daneshvar. Circulating Levels of Interleukin-35 in Patients with Multiple Sclerosis: Evaluation of the Influences of FOXP3 Gene Polymorphism and Treatment Program. *J Mol Neurosci* DOI 10.1007/s12031-014-0443-z
14. A. Jafarzadeh, H. A. Ebrahimi, S. Bagherzadeh, F. Zarkesh, F. Iranmanesh, A. Najafzadeh, A. Khosravimashizi, M. Nemati, A. Sabahi, H. Hajghani, H. Daneshvar, and M. M. Mohammadi, Lower Serum Levels of Th2-Related Chemokine

CCL22 in Women Patients with Multiple Sclerosis: A Comparison Between Patients and Healthy Women. *Inflammation* (# 2013) DOI: 10.1007/s10753-013-9775-z

15. A. Jafarzadeh, S. Bagherzadeh, H. A. Ebrahimi, H. Hajghani, M. R. Bazrafshani, A. Khosravimashizi, M. Nemati, F. Gadari, A. Sabahi, F. Iranmanesh, M. M. Mohammadi, H. Daneshvar, Higher Circulating Levels of Chemokine CCL20 in Patients with Multiple Sclerosis: Evaluation of the Influences of Chemokine Gene Polymorphism, Gender, Treatment and Disease Pattern. *J MolNeurosci* DOI 10.1007/s12031-013-0214-2

16. Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, et al. Quantification of chemical elements in the blood of patients affected by Multiple Sclerosis. *Ann Ist Super* 2005; 41: 213-16.

17. Rottem S, Naot Y (1998) *Subversion and exploitation of host cells by mycoplasmas. Trends Microbiol* 6:436–440.

18. Joel B. Baseman* and Joseph G. Tully Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety *Emerging Infectious Diseases* Vol. 3, No. 1—January-March 1997

19. Nicolson GL. Gulf War Illnesses—their causes and treatment. *Armed Forces Med. Dev.* 2001; 2:41-44. http://www.immed.org/publications/gulf_war_illness/AFMD-Nicolson2001.htm

20. Chris H Polman,¹ Stephen C Reingold,² Brenda Banwell,³ Michel Clanet,⁴ Jeffrey A Cohen,⁵ Massimo Filippi,⁶ Kazuo Fujihara,⁷ Eva Havrdova,⁸ Michael Hutchinson,⁹ Ludwig Kappos,¹⁰ Fred D Lublin,¹¹ Xavier Montalban,¹² Paul O'Connor,¹³ Magnhild Sandberg-Wollheim,¹⁴ Alan J Thompson,¹⁵ Emmanuelle Waubant,¹⁶ Brian Weinshenker,¹⁷ and Jerry S Wolinsky¹⁸ Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria.

Ann Neurol. 2011 Feb; 69(2): 292–302. doi: 10.1002/ana.22366 PMID: PMC3084507

21. Schumacher FA, Beeve GW, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis. *Ann N Y Acad Sci.* 1965; 122:552–568. [PubMed]

22. Poser CM, Paty DW, Scheinberg LC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Ann Neurol.* 1983; 1:227–231. [PubMed]

23. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. *Neurology.* 1988; 38:180–185. [PubMed]

24. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann Neurol.* 2001; 50:121–127. [PubMed]

25. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” *Ann Neurol.* 2005; 58:840–846. [PubMed]

26. Dalton CM, Brex PA, Miszkief KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. *Ann Neurol.* 2002; 52:47–53. [PubMed]

27. Tintoré M, Rovira A, Rio J, et al. New diagnostic criteria for multiple sclerosis. Application in first demyelinating episode. *Neurology.* 2003; 60:27–30. [PubMed]

28. Kojima A¹, Takahashi T, Kijima M, Ogikubo Y, Nishimura M, Nishimura S, Harasawa R, Tamura Y. Detection of Mycoplasma in avian live virus vaccines by polymerase chain reaction. *Biologicals.* 1997 Dec; 25(4):365-71.

29. Buonavoglia D, Greco G, Corrente M, Maria F Greco, D'Abramo M, Latronico F, Fasanella A, Nicola N, Long-term

immunogenicity and protection against *Mycoplasma agalactiae* induced by an oil adjuvant vaccine in sheep. Research in Veterinary Science Volume 88, Issue 1, February 2010, Pages 16–19

30. Kathleen A Stellrecht, Amy M Woron, Nada G Mishrik, Richard A Venezia, Comparison of Multiplex PCR assay with culture for detection of Genital mycoplasma. J Clinical Microbiol April 2004; 42(4): 1528-1533.

31. Tay ST¹, Habsah MY, Tan SC, Rohani MY. Detection of *Mycoplasma pneumoniae* from cerebrospinal fluid samples of pediatric patients. Southeast Asian J Trop Med Public Health. 2000 Dec; 31(4):684-7.

32. Lindsey J, Patel S. PCR for bacterial 16S ribosomal DNA in multiple sclerosis cerebrospinal fluid. MultScler 2008; 14: 147-52.

33. Casserly G, Barry T, Tourtellotte WW, Hogan EL. Absence of *Mycoplasma*-specific DNA sequence in brain, blood and CSF of patients with multiple sclerosis (MS): a study by PCR and real-time PCR. J NeuroSci 2007; 253: 48-52.

34. SamilehNoorbakhsh, Mehdi Shekerabi, ZohreKalbasi, azardokhtTabtabaei, Hasan Tonekaboni, Lada Afsharkhas, Mohammad VafaeShahi, Detection of mycoplasma pneumonia in cerebro-spinal fluid of children quantification of CSF IgG Antibody . Tehran University Medical Journal; Vol 68: No 5, Aug 2010; 274-280

35. Bahar M¹, Ashtari F, Aghaei M, Akbari M, Salari M, Ghalamkari S. *Mycoplasma pneumoniae* seropositivity in Iranian patients with relapsing-remitting multiple sclerosis: a randomized case-control study. J Pak Med Assoc. 2012 Mar; 62(3 Suppl 2):S6-8.

Investigating the Relationship between Nurses' Moral Sensitivity and Patients' Satisfaction with the Quality of Nursing Care

Department Nursing, Lecturer, Shushtar Faculty of Medical Sciences, Shushtar, Iran

*Corresponding Author: Department Nursing, Lecturer, Shushtar Faculty of Medical Sciences, Shushtar, Iran

Abstract

Background & Aims: Patient satisfaction is considered as an important indicator of the quality and effectiveness of health system. Moral sensitivity plays an important role in how professional responsibilities and moral decisions are made by nurses. This study aims to investigate the relationship between nurses' moral sensitivity and patients' satisfaction with quality of nursing care.

Materials & Methods: This study is descriptive and analytic. First, nurses in internal, surgical and special wards were selected through census method. Then, patients were selected using quota sampling to the ratio of nurses from each section. Data were collected through Demographic Questionnaires, Patient Satisfaction Instrument and Moral Sensitive Questions. Data were analyzed using SPSS 23.

Results: There was a significant positive correlation between nurses' moral sensitivity and patients' satisfaction with quality of nursing care ($P < 0.05$). The majority of patients (70.5%) had moderate level of satisfaction with quality of nursing care. 93.5% of nurses had high moral sensitivity. There was no statistically significant relationship between nurses' moral sensitivity and variables of sex, location of work, marital status, type of responsibility and work shift. Relationship between patient satisfaction and type of admission ward was significant ($P = 0.03$).

Conclusion: Increased moral sensitivity in nurses is effective on improving patients' satisfaction with the quality of nursing care. It is suggested to conduct further research with larger sample size and investigate other factors affecting patient satisfaction in order to ensure the generalizability of research results.

Key Words: Nurses' Moral Sensitivity, Patients' Satisfaction, Quality of Nursing Care

Ethics are set of behavioral characteristics originated from individual's beliefs, values, commitments, inner faith and piety and play a role in determination of attitudes and values (1). Moral sensitivity is the first component to observe ethics (2) and includes individual's skill and ability to interpret the reactions and feelings of others. This kind of sensitivity is effective on detection of moral conflicts, emotional and intellectual perceptions of vulnerable situations as well as increasing awareness of ethical consequences resulted from making decisions about others (3, 4). The attention paid to moral sensitivity is increasing especially in social fields and occupations (2). Nursing is a social profession (5). Due to the certain circumstances of their profession as well as providing acute and intensive care, nurses are regularly exposed to situations of conflict and tension caused by ethical confusions (6). Lack of attention to ethical issues by nurses may result in ignoring these